Prosecution Insights
Last updated: August 14, 2026
Application No. 18/675,875

4,4-DISUBSTITUTED CYCLOHEXYL BRIDGED HEPTAMETHINE CYANINE DYES AND USES THEREOF

Non-Final OA §DP
Filed
May 28, 2024
Priority
Mar 15, 2013 — provisional 61/798,562 +4 more
Examiner
JONES, DAMERON LEVEST
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Visen Medical Inc.
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
1y 3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
733 granted / 1082 resolved
+7.7% vs TC avg
Strong +31% interview lift
Without
With
+31.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
53 currently pending
Career history
1124
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
25.7%
-14.3% vs TC avg
§102
8.6%
-31.4% vs TC avg
§112
41.5%
+1.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1082 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Claim Status Claims 1-18 are pending. Priority This application is a CON of 17/454,300 filed 11/10/2021 (now abandoned); 17454300 is a CON of 16/654,305 filed 10/16/2019 (now US Patent No. 11,193,932); 16/654,305 is a CON of 15/890,646 filed 2/7/2018 (now US Patent No. 10,473,658); 15/890,646 is a DIV of 14/215,930 filed 3/17/2014 (now US Patent No. 9,897,604); and 14/215,930 claims benefit to PRO 61/798,562 filed 3/15/2013. Note(s): The earliest effective filing date is 3/15/2013 as the pending invention is fully supported in provisional application 61/798,562. Claim Interpretation Independent claim 1 is directed to fluorescent compound encompassed by Formula I-A, PNG media_image1.png 190 432 media_image1.png Greyscale , wherein the variables are as explained therein. Information Disclosure Statement The two information disclosure statements filed 7/17/2024 were considered. Double Patenting Rejections The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 9, 12, and 19-25 of U.S. Patent No. 9,897,604. Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims are directed to compounds encompassed by Applicant’s Formula I-A (see patented claims 9, 12, and 19-25). Thus, the skilled artisan would recognize that the inventions disclose overlapping subject matter. Claims 1-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 10, and 12 of U.S. Patent No. 11,193,932. Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims are directed to compounds encompassed by Applicant’s Formula I-A (see patented claims 1-5, 10, and 12). Thus, the skilled artisan would recognize that the inventions disclose overlapping subject matter. Comments/Notes It should be noted that no prior art is cited against the pending invention. The claims are distinguished over the prior art of record because the prior art neither anticipates nor renders obvious compounds of Formula I-A as set forth herein. The closest art is Applicant’s own work which is cited in the double patenting rejections above. Conclusion Claims 1-18 are rejected. Future Correspondences Any inquiry concerning this communication or earlier communications from the examiner should be directed to D L Jones whose telephone number is (571)272-0617. The examiner can normally be reached M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael G. Hartley can be reached at (571)272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D. L. Jones/ Primary Patent Examiner Art Unit 1618 July 18, 2026
Read full office action

Prosecution Timeline

May 28, 2024
Application Filed
Jul 22, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12697401
THROMBUS IMAGING APTAMERS AND METHODS OF USING SAME
3y 7m to grant Granted Aug 04, 2026
Patent 12697404
PSMA-TARGETING CONJUGATE AND USES THEREOF
3y 0m to grant Granted Aug 04, 2026
Patent 12691185
METHODS OF SEQUESTERING TARGET ELEMENTS
5y 5m to grant Granted Jul 28, 2026
Patent 12692278
SYNTHESIS METHODS AND COMPOSITIONS OF LOW INTERMEDIATE AND LOW DICHELATE INTERMEDIATE CONTRAST AGENTS
4y 5m to grant Granted Jul 28, 2026
Patent 12691186
B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF
9m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+31.3%)
3y 5m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1082 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month